Akari Common Stock Total Equity vs Total Current Liabilities Analysis

AKTX Stock  USD 1.21  0.09  8.04%   
Akari Therapeutics financial indicator trend analysis is way more than just evaluating Akari Therapeutics PLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Akari Therapeutics PLC is a good investment. Please check the relationship between Akari Therapeutics Common Stock Total Equity and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Common Stock Total Equity vs Total Current Liabilities

Common Stock Total Equity vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Akari Therapeutics PLC Common Stock Total Equity account and Total Current Liabilities. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Akari Therapeutics' Common Stock Total Equity and Total Current Liabilities is 0.47. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Akari Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Akari Therapeutics' Common Stock Total Equity and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Akari Therapeutics PLC are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Common Stock Total Equity i.e., Akari Therapeutics' Common Stock Total Equity and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.47
Relationship DirectionPositive 
Relationship StrengthWeak

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Total Current Liabilities

Total Current Liabilities is an item on Akari Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Akari Therapeutics PLC are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Akari Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Akari Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Selling General Administrative is likely to drop to about 7.6 M in 2024. Tax Provision is likely to drop to about (3 M) in 2024
 2021 2022 2023 2024 (projected)
Net Interest Income10.6K45.9K41.3K70.5K
Interest Income10.6K45.9K41.3K39.3K

Akari Therapeutics fundamental ratios Correlations

0.730.660.660.73-0.71-0.160.420.710.730.830.63-0.350.20.640.730.64-0.450.930.01-0.45-0.55-0.540.790.270.6
0.730.850.880.99-0.990.060.740.991.00.40.59-0.230.140.881.00.58-0.430.86-0.12-0.43-0.49-0.470.870.050.93
0.660.850.990.77-0.86-0.260.570.860.850.330.48-0.220.360.990.850.49-0.440.680.12-0.44-0.56-0.530.790.10.79
0.660.880.990.81-0.89-0.230.690.890.880.310.47-0.170.351.00.880.47-0.40.690.12-0.4-0.55-0.520.820.10.83
0.730.990.770.81-0.970.120.730.970.990.420.58-0.230.070.810.990.58-0.440.88-0.15-0.44-0.46-0.440.850.070.92
-0.71-0.99-0.86-0.89-0.97-0.07-0.74-1.0-0.99-0.33-0.550.25-0.12-0.89-0.99-0.550.42-0.840.120.420.460.44-0.840.01-0.91
-0.160.06-0.26-0.230.12-0.07-0.080.070.08-0.290.03-0.53-0.92-0.210.060.010.580.11-0.870.580.660.68-0.28-0.270.11
0.420.740.570.690.73-0.74-0.080.740.720.120.240.130.220.680.740.24-0.20.510.13-0.2-0.38-0.360.690.070.76
0.710.990.860.890.97-1.00.070.740.990.330.55-0.250.110.890.990.55-0.410.84-0.12-0.41-0.46-0.440.84-0.020.91
0.731.00.850.880.99-0.990.080.720.990.380.56-0.270.10.881.00.56-0.410.86-0.13-0.41-0.46-0.440.840.060.93
0.830.40.330.310.42-0.33-0.290.120.330.380.66-0.130.330.30.40.66-0.450.710.04-0.45-0.55-0.540.660.180.21
0.630.590.480.470.58-0.550.030.240.550.560.66-0.360.040.490.591.0-0.350.73-0.42-0.35-0.44-0.420.76-0.110.36
-0.35-0.23-0.22-0.17-0.230.25-0.530.13-0.25-0.27-0.13-0.360.63-0.19-0.23-0.36-0.23-0.420.6-0.23-0.23-0.23-0.02-0.17-0.23
0.20.140.360.350.07-0.12-0.920.220.110.10.330.040.630.330.140.05-0.640.010.79-0.64-0.73-0.750.440.040.05
0.640.880.991.00.81-0.89-0.210.680.890.880.30.49-0.190.330.880.5-0.40.690.09-0.4-0.53-0.50.820.090.83
0.731.00.850.880.99-0.990.060.740.991.00.40.59-0.230.140.880.58-0.430.86-0.11-0.43-0.49-0.470.870.050.93
0.640.580.490.470.58-0.550.010.240.550.560.661.0-0.360.050.50.58-0.360.73-0.4-0.36-0.45-0.430.76-0.090.37
-0.45-0.43-0.44-0.4-0.440.420.58-0.2-0.41-0.41-0.45-0.35-0.23-0.64-0.4-0.43-0.36-0.37-0.521.00.830.82-0.57-0.16-0.27
0.930.860.680.690.88-0.840.110.510.840.860.710.73-0.420.010.690.860.73-0.37-0.26-0.37-0.48-0.460.830.060.72
0.01-0.120.120.12-0.150.12-0.870.13-0.12-0.130.04-0.420.60.790.09-0.11-0.4-0.52-0.26-0.52-0.49-0.510.050.39-0.04
-0.45-0.43-0.44-0.4-0.440.420.58-0.2-0.41-0.41-0.45-0.35-0.23-0.64-0.4-0.43-0.361.0-0.37-0.520.830.82-0.57-0.16-0.27
-0.55-0.49-0.56-0.55-0.460.460.66-0.38-0.46-0.46-0.55-0.44-0.23-0.73-0.53-0.49-0.450.83-0.48-0.490.830.99-0.71-0.13-0.34
-0.54-0.47-0.53-0.52-0.440.440.68-0.36-0.44-0.44-0.54-0.42-0.23-0.75-0.5-0.47-0.430.82-0.46-0.510.820.99-0.69-0.17-0.33
0.790.870.790.820.85-0.84-0.280.690.840.840.660.76-0.020.440.820.870.76-0.570.830.05-0.57-0.71-0.690.010.71
0.270.050.10.10.070.01-0.270.07-0.020.060.18-0.11-0.170.040.090.05-0.09-0.160.060.39-0.16-0.13-0.170.010.24
0.60.930.790.830.92-0.910.110.760.910.930.210.36-0.230.050.830.930.37-0.270.72-0.04-0.27-0.34-0.330.710.24
Click cells to compare fundamentals

Akari Therapeutics Account Relationship Matchups

Akari Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding915.5K1.6M2.1M3.1M4.9M4.7M
Total Assets10.3M17.6M11.6M13.8M4.4M4.1M
Other Current Liab4.2M1.8M4.3M11.1M2.9M5.7M
Total Current Liabilities5.5M5.2M6.1M12.0M4.6M7.9M
Total Stockholder Equity3.8M12.4M5.6M1.8M(229K)(217.6K)
Net Debt(5.7M)(14.1M)(9.4M)(13.2M)(3.8M)(4.0M)
Retained Earnings(138.2M)(156.6M)(199.7M)(217.5M)(227.5M)(216.1M)
Accounts Payable1.2M3.4M1.8M947K1.7M2.1M
Cash5.7M14.1M9.4M13.2M3.8M3.7M
Cash And Short Term Investments5.7M14.1M9.4M13.2M3.8M3.7M
Common Stock Total Equity22.9M23.7M32.0M384.7K442.4K420.3K
Liabilities And Stockholders Equity10.3M17.6M11.6M13.8M4.4M4.1M
Non Current Liabilities Total1.0M3.4M4.3M946.7K1.1M1.1M
Other Stockholder Equity122.3M191.9M205.3M219.3M174.8M117.1M
Total Liab6.5M5.2M6.1M12.0M4.6M8.1M
Total Current Assets10.3M17.6M11.6M13.8M4.3M4.1M
Accumulated Other Comprehensive Income(12.2M)(10.9M)(541.0K)(770.8K)51.2M53.7M
Common Stock32.0M385K476.0K744.5K1.3M1.3M
Non Current Assets Total35K27K22.9K16.9K14K13.3K
Property Plant And Equipment Gross20.4K5.0K172K164.9K197.8K207.7K
Intangible Assets30K27K22.9K16.9K14K13.3K
Net Tangible Assets3.1M(1.8M)9.4M5.5M5.0M4.7M
Non Currrent Assets Other142.2K585K0.014.0K16.1K15.3K
Other Current Assets1.0M521.9K2.3M564.8K496K954.4K
Net Invested Capital(1.8M)9.4M5.6M1.8M1.6M1.5M
Net Working Capital(1.8M)9.4M5.5M1.8M1.6M1.5M
Capital Stock32.0M384.7K476.0K744.5K670.0K636.5K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.